دورية أكاديمية
Tirbanibulin decreases cell proliferation and downregulates protein expression of oncogenic pathways in human papillomavirus containing HeLa cells.
| العنوان: | Tirbanibulin decreases cell proliferation and downregulates protein expression of oncogenic pathways in human papillomavirus containing HeLa cells. |
|---|---|
| المؤلفون: | Moore S; Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA.; Department of Biosciences, Rice University, Houston, TX, USA., Kulkarni V; Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA., Moore A; Department of Dermatology, Baylor University Medical Center Part of Baylor Scott and White, Dallas, TX, USA., Landes JR; Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA., Simonette R; Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA., He Q; Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA., Rady PL; Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA., Tyring SK; Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA. styring@ccstexas.com. |
| المصدر: | Archives of dermatological research [Arch Dermatol Res] 2024 Jul 05; Vol. 316 (7), pp. 455. Date of Electronic Publication: 2024 Jul 05. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8000462 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-069X (Electronic) Linking ISSN: 03403696 NLM ISO Abbreviation: Arch Dermatol Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin : Springer Verlag |
| مواضيع طبية MeSH: | Cell Proliferation*/drug effects , Oncogene Proteins, Viral*/metabolism , Down-Regulation*/drug effects , Human papillomavirus 18*, Humans ; HeLa Cells ; Papillomavirus Infections/virology ; Papillomavirus Infections/drug therapy ; Papillomavirus E7 Proteins/metabolism ; Apoptosis/drug effects ; Repressor Proteins/metabolism ; Repressor Proteins/genetics ; Signal Transduction/drug effects ; Uterine Cervical Neoplasms/virology ; Uterine Cervical Neoplasms/drug therapy ; Uterine Cervical Neoplasms/pathology ; Uterine Cervical Neoplasms/metabolism ; src-Family Kinases/metabolism ; src-Family Kinases/antagonists & inhibitors ; Female ; Human Papillomavirus Viruses ; DNA-Binding Proteins |
| مستخلص: | Tirbanibulin 1% ointment is a synthetic antiproliferative agent approved in 2021 by the European Union for treating actinic keratoses (AK). Topical tirbanibulin has clinically resolved HPV-57 ( +) squamous cell carcinoma (SCC), HPV-16 ( +) vulvar high-grade squamous intraepithelial lesion, epidermodysplasia verruciformis, and condyloma. We examined how tirbanibulin might affect HPV oncoprotein expression and affect other cellular pathways involved in cell proliferation and transformation. We treated the HeLa cell line, containing integrated HPV-18, with increasing doses of tirbanibulin to determine the effects on cell proliferation. Immunoblotting was performed with antibodies against the Src canonical pathway, HPV 18 E6 and E7 transcription regulation, apoptosis, and invasion and metastasis pathways. Cell proliferation assays with tirbanibulin determined the half-maximal inhibitory concentration (IC (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| References: | Blauvelt A, Kempers S, Lain E et al (2021) Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med 384(6):512–520. https://doi.org/10.1056/NEJMoa2024040. (PMID: 10.1056/NEJMoa202404033567191) Moore A, Hurley K, Moore S, Moore L (2023) Topical tirbanibulin resolves recalcitrant condyloma acuminata: retrospective case series. JAAD Case Rep. https://doi.org/10.1016/j.jdcr.2023.04.011. (PMID: 10.1016/j.jdcr.2023.04.0113784215310477357) Moore AY, Moore SA, He Q, Rady P, Tyring SK (2022) Tirbanibulin 1% ointment eradicates HPV-16 (+) vulvar high-grade squamous intraepithelial lesion. J Eur Acad Dermatol Venereol 36(10):e784–e785. https://doi.org/10.1111/jdv.18265. (PMID: 10.1111/jdv.1826535608184) Moore AY, Moore SA, He Q, Rady P, Tyring SK (2022) HPV-57 (+) in periungual squamous cell carcinoma eradicated by topical tirbanibulin. JAAD Case Rep. Published online February 10. https://doi.org/10.1016/j.jdcr.2022.01.021. Bunda S, Heir P, Srikumar T et al (2014) Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation. Proc Natl Acad Sci U S A 111(36):E3785-3794. https://doi.org/10.1073/pnas.1406559111. (PMID: 10.1073/pnas.1406559111251571764246987) Stokoe D, McCormick F (1997) Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro. EMBO J 16(9):2384–2396. https://doi.org/10.1093/emboj/16.9.2384. (PMID: 10.1093/emboj/16.9.238491713521169839) Schlesinger T, Stockfleth E, Grada A, Berman B (2022) Tirbanibulin for actinic keratosis: insights into the mechanism of action. Clin Cosmet Investig Dermatol 15:2495–2506. https://doi.org/10.2147/CCID.S374122. (PMID: 10.2147/CCID.S374122364155419675993) Pelaz SG, Tabernero A (2022) Src: coordinating metabolism in cancer. Oncogene 41(45):4917–4928. https://doi.org/10.1038/s41388-022-02487-4. (PMID: 10.1038/s41388-022-02487-4362170269630107) Wang J, Aldabagh B, Yu J, Arron ST (2014) Role of human papillomavirus in cutaneous squamous cell carcinoma: a Meta-analysis. J Am Acad Dermatol 70(4):621–629. https://doi.org/10.1016/j.jaad.2014.01.857. (PMID: 10.1016/j.jaad.2014.01.857246293583959664) Kim S, Min A, Lee KH et al (2017) Antitumor effect of KX-01 through inhibiting Src family kinases and mitosis. Cancer Res Treat 49(3):643–655. https://doi.org/10.4143/crt.2016.168. (PMID: 10.4143/crt.2016.16827737538) Gilaberte Y, Fernández-Figueras MT (2021) Tirbanibulin: review of its novel mechanism of action and how it fits into the treatment of actinic keratosis. Actas Dermo-Sifiliográficas Engl Ed. https://doi.org/10.1016/j.adengl.2021.11.010. (PMID: 10.1016/j.adengl.2021.11.010) Szalmás A, Gyöngyösi E, Ferenczi A et al (2013) Activation of Src, Fyn and Yes non-receptor tyrosine kinases in keratinocytes expressing human papillomavirus (HPV) type 16 E7 oncoprotein. Virol J 10(1):79. https://doi.org/10.1186/1743-422X-10-79. (PMID: 10.1186/1743-422X-10-79234973023608944) Kong L, Deng Z, Zhao Y, Wang Y, Sarkar FH, Zhang Y (2011) Down-regulation of phospho-non-receptor Src tyrosine kinases contributes to growth inhibition of cervical cancer cells. Med Oncol Northwood Lond Engl 28(4):1495–1506. https://doi.org/10.1007/s12032-010-9583-3. (PMID: 10.1007/s12032-010-9583-3) Pal A, Kundu R (2020) Human papillomavirus E6 and E7: The cervical cancer hallmarks and targets for therapy. Front Microbiol 10:3116. https://doi.org/10.3389/fmicb.2019.03116. (PMID: 10.3389/fmicb.2019.03116320385576985034) Morales-Garcia V, Contreras-Paredes A, Martinez-Abundis E et al (2020) The high-risk HPV E6 proteins modify the activity of the eIF4E protein via the MEK/ERK and AKT/PKB pathways. FEBS Open Bio 10(12):2541–2552. https://doi.org/10.1002/2211-5463.12987. (PMID: 10.1002/2211-5463.12987329812207714072) Gao SY, Li EM, Cui L et al (2009) Sp1 and AP-1 regulate expression of the human gene VIL2 in esophageal carcinoma cells. J Biol Chem 284(12):7995–8004. https://doi.org/10.1074/jbc.M809734200. (PMID: 10.1074/jbc.M809734200191642832658093) Siddiqui N, Sonenberg N (2015) Signalling to eIF4E in cancer. Biochem Soc Trans 43(5):763–772. https://doi.org/10.1042/BST20150126. (PMID: 10.1042/BST20150126265178814613458) Idres YM, Lai AJ, McMillan NAJ, Idris A (2023) Hyperactivation of p53 using CRISPRa kills human papillomavirus-driven cervical cancer cells. Virus Genes 59(2):312–316. https://doi.org/10.1007/s11262-022-01960-2. (PMID: 10.1007/s11262-022-01960-236474086) Shu KX, Li B, Wu LX (2007) The p53 network: p53 and its downstream genes. Colloids Surf B Biointerfaces 55(1):10–18. https://doi.org/10.1016/j.colsurfb.2006.11.003. (PMID: 10.1016/j.colsurfb.2006.11.00317188467) Drosten M, Sum EYM, Lechuga CG et al (2014) Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway. Proc Natl Acad Sci USA 111(42):15155–15160. https://doi.org/10.1073/pnas.1417549111. (PMID: 10.1073/pnas.1417549111252887564210339) Montero J, Dutta C, van Bodegom D, Weinstock D, Letai A (2013) p53 regulates a non-apoptotic death induced by ROS. Cell Death Differ 20(11):1465–1474. https://doi.org/10.1038/cdd.2013.52. (PMID: 10.1038/cdd.2013.52237033223792438) Chaitanya GV, Alexander JS, Babu PP (2010) PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 8(1):31. https://doi.org/10.1186/1478-811X-8-31. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG (1993) Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53(17):3976–3985. (PMID: 8358726) Antonucci LA, Egger JV, Krucher NA (2014) Phosphorylation of the Retinoblastoma protein (Rb) on serine-807 is required for association with Bax. Cell Cycle 13(22):3611–3617. https://doi.org/10.4161/15384101.2014.964093. (PMID: 10.4161/15384101.2014.964093254830964614104) Yoon H, Dehart JP, Murphy JM, Lim STS (2015) Understanding the roles of FAK in cancer. J Histochem Cytochem 63(2):114–128. https://doi.org/10.1369/0022155414561498. (PMID: 10.1369/002215541456149825380750) Luo J, Zou H, Guo Y et al (2022) SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. Breast Cancer Res 24(1):99. https://doi.org/10.1186/s13058-022-01596-y. (PMID: 10.1186/s13058-022-01596-y365819089798727) Wu Y, Li N, Ye C et al (2021) Focal adhesion kinase inhibitors, a heavy punch to cancer. Discov Oncol 12:52. https://doi.org/10.1007/s12672-021-00449-y. (PMID: 10.1007/s12672-021-00449-y352014858777493) Li J, Zhang X, Hou Z et al (2022) P130cas-FAK interaction is essential for YAP-mediated radioresistance of non-small cell lung cancer. Cell Death Dis 13(9):1–15. https://doi.org/10.1038/s41419-022-05224-7. (PMID: 10.1038/s41419-022-05224-7) Kumbrink J, Kirsch KH, Kumbrink J, Kirsch KH (2011) Targeting cas family proteins as a novel treatment for breast cancer. In: Breast cancer - current and alternative therapeutic modalities. IntechOpen https://doi.org/10.5772/21227. Jackson RJ, Hellen CUT, Pestova TV (2010) The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 11(2):113–127. https://doi.org/10.1038/nrm2838. (PMID: 10.1038/nrm2838200940524461372) Zhu Y, Wang C, Li M, Yang X (2021) Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer. J Pharm Pharmacol 73(10):1418–1426. https://doi.org/10.1093/jpp/rgab094. (PMID: 10.1093/jpp/rgab09434254647) Zhang W, Su X, Li S, Wang Y, Wang Q, Zeng H (2019) Inhibiting MNK selectively targets cervical cancer via suppressing eIF4E-mediated β-catenin activation. Am J Med Sci 358(3):227–234. https://doi.org/10.1016/j.amjms.2019.05.013. (PMID: 10.1016/j.amjms.2019.05.01331327462) Sears RC, Nevins JR (2002) Signaling networks that link cell proliferation and cell fate*. J Biol Chem 277(14):11617–11620. https://doi.org/10.1074/jbc.R100063200. (PMID: 10.1074/jbc.R10006320011805123) Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M (2021) MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol OncolJ Hematol Oncol 14(1):121. https://doi.org/10.1186/s13045-021-01111-4. (PMID: 10.1186/s13045-021-01111-4) García-Gutiérrez L, Delgado MD, León J (2019) MYC oncogene contributions to release of cell cycle brakes. Genes 10(3):244. https://doi.org/10.3390/genes10030244. (PMID: 10.3390/genes10030244309094966470592) De Zio D, Cianfanelli V, Cecconi F (2013) New Insights into the link between DNA damage and apoptosis. Antioxid Redox Signal 19(6):559–571. https://doi.org/10.1089/ars.2012.4938. (PMID: 10.1089/ars.2012.4938230254163717195) Caner A, Asik E, Ozpolat B (2021) SRC Signaling in cancer and tumor microenvironment. In: Birbrair A, ed. Tumor microenvironment: signaling pathways – Part B. Advances in experimental medicine and biology. Springer International Publishing; https://doi.org/10.1007/978-3-030-47189-7_4. Morgan EL, Scarth JA, Patterson MR et al (2021) E6-mediated activation of JNK drives EGFR signalling to promote proliferation and viral oncoprotein expression in cervical cancer. Cell Death Differ 28(5):1669–1687. https://doi.org/10.1038/s41418-020-00693-9. (PMID: 10.1038/s41418-020-00693-933303976) Wheeler DL, Iida M, Dunn EF (2009) The role of Src in solid tumors. Oncologist 14(7):667–678. https://doi.org/10.1634/theoncologist.2009-0009. (PMID: 10.1634/theoncologist.2009-000919581523) Moumen A, Patané S, Porras A, Dono R, Maina F (2007) Met acts on Mdm2 via mTOR to signal cell survival during development. Development 134(7):1443–1451. https://doi.org/10.1242/dev.02820. (PMID: 10.1242/dev.0282017329361) Haura EB (2006) SRC and STAT pathways. J Thorac Oncol 1(5):403–405. https://doi.org/10.1016/S1556-0864(15)31601-4. (PMID: 10.1016/S1556-0864(15)31601-417409890) Kung CP, Weber JD (2022) It’s getting complicated—a fresh look at p53-MDM2-ARF triangle in tumorigenesis and cancer therapy. Front Cell Dev Biol. Accessed October 9, 2023. https://www.frontiersin.org/articles/ https://doi.org/10.3389/fcell.2022.818744. |
| فهرسة مساهمة: | Keywords: Human papillomavirus; Novel treatment; Skin disease; Tirbanibulin; Topical treatment Local Abstract: [plain-language-summary] Tirbanibulin is Promising Novel Therapy for Human Papillomavirus (HPV)-associated Diseases.Tirbanibulin 1% ointment is an approved synthetic topical ointment for treating actinic keratoses (AK), a precancer of skin cancer. Topical tirbanibulin has previously been reported to clinically resolve human papillomavirus (HPV)-( +) diseases.In this study, we examine how tirbanibulin may affect the HPV and pathways associated with cancer.We treated the HeLa cell line to determine the effects on HPV cell proliferation. Increasing the concentration of tirbanibulin statistically significantly affected numerous cellular pathways often associated with cancer.These results demonstrate that tirbanibulin may impact expression of HPV oncoproteins and thereby kill cancer cells. |
| المشرفين على المادة: | 0 (Oncogene Proteins, Viral) 0 (E6 protein, Human papillomavirus type 18) 0 (E7 protein, Human papillomavirus type 18) 0 (Papillomavirus E7 Proteins) 0 (Repressor Proteins) EC 2.7.10.2 (src-Family Kinases) 0 (DNA-Binding Proteins) |
| تواريخ الأحداث: | Date Created: 20240705 Date Completed: 20240705 Latest Revision: 20240705 |
| رمز التحديث: | 20240705 |
| DOI: | 10.1007/s00403-024-03205-8 |
| PMID: | 38967656 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-069X |
|---|---|
| DOI: | 10.1007/s00403-024-03205-8 |